EMVision Advances Stroke Diagnosis Trials with UCLA Activation

EMvision Medical Devices Ltd. ( (AU:EMV) ) has issued an update.

EMVision Medical Devices Ltd announced the activation of UCLA Health as the final site for their Pivotal Trial, which is crucial for their De Novo submission to the FDA. The trial aims to assess the diagnostic performance of their emu™ brain scanner in detecting acute strokes. The company is on track to meet its recruitment targets by the first half of 2026. Additionally, a Trial Steering Committee comprising international stroke experts has been established to provide strategic guidance, enhancing the trial’s credibility and potential for regulatory approval.

The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.

More about EMvision Medical Devices Ltd.

EMVision Medical Devices Ltd is a company in the medical technology industry, focusing on developing innovative diagnostic tools. Their primary product is the emu™ brain scanner, designed to aid in the assessment of patients with suspected acute stroke. The company is actively involved in clinical trials to validate the effectiveness of their device, with a market focus on improving stroke diagnosis and care.

Average Trading Volume: 29,302

Technical Sentiment Signal: Hold

Current Market Cap: A$157.4M

Find detailed analytics on EMV stock on TipRanks’ Stock Analysis page.